NCT07415005 2026-02-17
Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
M.D. Anderson Cancer Center
Regeneron Pharmaceuticals
Qingdao Sino-Cell Biomedicine Co., Ltd.
Shenyang Sunshine Pharmaceutical Co., LTD.